The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Data published in Neurology suggest long-term benefit of Spinraza™ treatment in later-onset SMA, including SMA type III

    long-term benefit of Spinraza™ treatment in later-onset SMABiogen has announced that data from a study on the safety and tolerability of Spinraza™ in individuals with later-onset SMA had been published in the peer-reviewed journal Neurology.

    Twenty eight patients, aged 5 to 19, who have, or are most likely to develop SMA type II or III were treated with Spinraza™ for over three years. The results showed that these patients regained motor function that had previously been lost and that this treatment stabilised their condition, leading to improvements in daily living activities. These findings were not observed in untreated people with SMA.

    For more information